Drugs / IPN60090
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05039801 | Sep 2021 → Mar 2028 expected | chondrosarcoma, cutaneous melanoma, endometrial carcinoma, head and neck squamous cell carcinoma +3 | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03894540 | Mar 2019 → Dec 2020 | cancer | Ipsen | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPN60090 | “IPN60090” NCT05039801 ↗ |
| Known as | IACS-6274 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05039801 ↗ |
| Action | Inhibit | “oral glutaminase inhibitor IPN60090 (IACS-6274)” NCT05039801 ↗ |
| Modality | Small molecule | — CHEMBL4741924 ↗ |
| Route | Oral | “IPN60090 given as a Bis in Die (BID) oral dose administered up to Maximum Tolerated Dose (MTD) over a 21-day cycle” NCT03894540 ↗ |